The Addition of Probiotic Consumption to a Nutritional Intervention and Caloric Restriction on Body Weight and Composition in Overweight Participants

NCT ID: NCT02962583

Last Updated: 2020-09-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

152 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-31

Study Completion Date

2019-06-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Limited interventional human studies suggest that probiotic supplementation may be a beneficial strategy for promoting weight loss when added to a nutritional intervention via their effects on lipid absorption and metabolic signaling molecules. The purpose of this study is to evaluate the effects of addition of a probiotic supplementation to a weight loss intervention on body weight, body composition and overall health in overweight adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotic

Daily probiotic consumption

Group Type EXPERIMENTAL

Weight loss

Intervention Type OTHER

Probiotic Formula

Intervention Type DRUG

Placebo

Daily placebo consumption

Group Type PLACEBO_COMPARATOR

Weight loss

Intervention Type OTHER

Placebos

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Weight loss

Intervention Type OTHER

Probiotic Formula

Intervention Type DRUG

Placebos

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 to 55 years
* BMI between 27.0 and 39.9 kg/m2
* Sedentary to moderate active (less than 30 minutes of physical activity, 3 times per week)
* Willingness to complete questionnaires, records, and diaries associated with the study and to complete all study visits
* Willingness to discontinue consumption of fermented foods or probiotics (e.g. yoghourts, with live, active cultures or supplements), laxatives, prebiotics and any substance for body weight control
* Willingness and ability to provide informed consent in French
* Willingness to receive random assignment to probiotic or placebo supplementation
* Committed to losing weight over the 12-week study period

Exclusion Criteria

* Smokers
* Use of another investigational product within three months of the pre-baseline period.
* Known to be pregnant or breast-feeding or planning on becoming pregnant in the next 18 months.

* Women of child-bearing potential not using effective contraception which include:
* Hormonal contraceptives including combined oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormonal implants
* Intrauterine devices (IUD) or Intrauterine system (IUS)
* Tubal ligation
* Vasectomy of partner
* Double barrier method (use of physical barrier by both partners, e.g. male condom and diaphragm, male condom and cervical cap)
* Positive pregnancy test in women of child-bearing potential
* Menopausal women
* Allergic to milk, soy, or yeast
* Weight gain or loss of at least 10 lbs in previous three months
* Inflammatory bowel syndrome, celiac disease, short bowel syndrome, or any other malabsorptive syndrome
* Uncontrolled angina within the past six months
* Insulin-dependent diabetes (oral medications are not exclusionary)
* Serious and/or unstable medical conditions (e.g. cardiovascular, renal, lung, psychiatric illness, bleeding disorders, etc.)
* Cancer treatment (radiation, chemotherapy, surgery) within past six months or any other treatment or condition known to weaken the immune system (such as systemic corticosteroids or HIVIAIDS).
* Any physical condition deemed likely to significantly interfere with individuals' ability to participate in a nutritional intervention.
* Currently or at any point during the study participating in Weight Watcher's or another weight loss program or taking a medication for weight loss.
* Under antibiotics or treatments (medication or nutritional program) affecting body weight Intake and/or energy expenditure
* History of drug or alcohol (\> 9 drinks weekly) abuse
* Abnormal thyroid hormone levels
* Immune-compromised conditions
* Participant experiencing nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lallemand Health Solutions

INDUSTRY

Sponsor Role collaborator

Laval University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Angelo Tremblay

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Angelo Tremblay, Ph.D

Role: STUDY_DIRECTOR

Laval University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

PEPS - Université Laval

Québec, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Choi BS, Brunelle L, Pilon G, Cautela BG, Tompkins TA, Drapeau V, Marette A, Tremblay A. Lacticaseibacillus rhamnosus HA-114 improves eating behaviors and mood-related factors in adults with overweight during weight loss: a randomized controlled trial. Nutr Neurosci. 2023 Jul;26(7):667-679. doi: 10.1080/1028415X.2022.2081288. Epub 2022 Jun 17.

Reference Type DERIVED
PMID: 35714163 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLIN-21-012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Probiotics for Weight Loss
NCT04897698 COMPLETED NA
Probiotic Intervention Study
NCT06030362 RECRUITING NA
Probiotics on Sleep Among Adults Study
NCT04767997 COMPLETED PHASE2
Probiotics and Endotoxemia
NCT01176942 COMPLETED NA
Probiotics in Obesity Management
NCT06964932 COMPLETED NA
Probiotics and Gut Health
NCT03418857 RECRUITING PHASE1/PHASE2